Morning Star | Four Qiming Venture Partners Portfolio Companies Named to NetEase Future Awards 2025 Annual AI List
These companies and individuals are not only the focus of venture capital and industry attention, but have also largely shaped the trajectory of China's AI development.
The 2025 NetEase Future Conference recently opened in Hangzhou, with the annual NetEase Future Awards officially announced. This year's awards recognized the Top 10 Most Influential AI Companies, Top 10 Embodied AI Pioneer Companies, Top 10 AI Agent Innovative Companies, and Top 10 Most Influential AI Figures. Portfolio companies of Qiming Venture Partners — Zhipu AI, Galaxy Universal, UBTECH (09880.HK), and StepFun — were selected.
Zhipu AI
Selected for
Top 10 Most Influential AI Companies of the Year
Galaxy Universal, UBTECH
Selected for
Top 10 Embodied AI Pioneer Companies of the Year
Zhipu AI — AutoGLM
Selected for
Top 10 AI Agent Innovative Companies of the Year
Zhipu AI CEO Zhang Peng
StepFun Founder and CEO Daxin Jiang
Selected for
Top 10 Most Influential AI Figures
Selection Criteria
The results were determined through nominations and voting by partners from nearly 20 active frontline investment firms and industry research institutions.
The NetEase Future Awards noted that these companies and individuals represent the focus of venture capital and industry attention, and have significantly shaped the trajectory of China's AI development. This list serves as both a record of the past year's industrial landscape and a reflection of the directions most likely to see sustained investment and breakthroughs in the coming years.
Source | NetEase Technology
Past Highlights
Qiming View | Technology Growing Upward, Applications Taking Root — AI Resonance Cycle and Top 10 AI Outlooks for 2025 Qiming Headlines | 2025 WAIC "Qiming Venture Partners · Entrepreneurship and Investment Forum — Venture Capital Enters the AI Technology and Application Resonance Cycle" Successfully Held Qiming Honors | Qiming Venture Partners Wins Three Awards Including China Venture Capital Research Institute · 2025 China Venture Capital Industry Annual Golden Investment Award
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns in their industries.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Genrix Bio (688520.SH), Hoba Therapeutics, Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.